WO2001020995A1 - Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof - Google Patents
Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof Download PDFInfo
- Publication number
- WO2001020995A1 WO2001020995A1 PCT/US2000/026177 US0026177W WO0120995A1 WO 2001020995 A1 WO2001020995 A1 WO 2001020995A1 US 0026177 W US0026177 W US 0026177W WO 0120995 A1 WO0120995 A1 WO 0120995A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- substituted
- unsubstituted
- linker
- compounds
- Prior art date
Links
- RTCLESLCOSPPDD-UHFFFAOYSA-N OC(CN(CCC1=CNC2C=CC=CC12)C(C1=Cc(c(cccc2)c2cc2)c2OC1=O)=O)=O Chemical compound OC(CN(CCC1=CNC2C=CC=CC12)C(C1=Cc(c(cccc2)c2cc2)c2OC1=O)=O)=O RTCLESLCOSPPDD-UHFFFAOYSA-N 0.000 description 1
- HPVLUHTXWWJJHM-UHFFFAOYSA-N OCc(ccc(C(O)=O)c1)c1F Chemical compound OCc(ccc(C(O)=O)c1)c1F HPVLUHTXWWJJHM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
Definitions
- the invention relates to novel compounds and compositions which inhibit or prevent bacterial growth and/or attachment by inhibiting or preventing pilus biogenesis. Further provided are fluorinated linker compositions bound to a solid support for solid phase synthesis of N-substituted amino acid compositions, as well as derivatives of carboxylic acids in general.
- Pili are thought to mediate microbial attachment, often the essential first step in the development of disease, by binding to receptors present in host tissues and may also participate in bacterial-bacterial interactions important in biofilm formation.
- Uropathogenic strains of E. coli express type 1 and P pili that bind to receptors present in uroepithelial cells. Type 1 appear to be more common in E. coli causing cystitis whereas adhesive P pili are virulence determinants associated with pyelonephritic strains of E. coli.
- Type 1 pili are adhesive fibers expressed in E. coli as well as in most of the Enterobacteriaceae family. They are composite structures in which a short tip fibrillar structure containing FimG and the FimH adhesin (and possibly the minor component FimF as well) is joined to a rod comprised predominantly of FimA subunits.
- the type 1 adhesin, FimH binds D-mannose oligosaccharides present in glycolipids and glycoproteins. In uropathogenic E. coli, this binding event has been shown to play a critical role in bladder colonization and disease.
- Type 1 pilus biogenesis proceeds via a highly conserved chaperone/usher pathway that is involved in the assembly of over 25 adhesive organelles in Gram-negative bacteria.
- P pili are adhesive organelles encoded by eleven genes in the pap (pilus associated with pyelonephritis) gene cluster found on the chromosome of uropathogenic strains of E. coli.
- Six genes encode structural pilus subunits, PapA, PapH, PapK, Pap ⁇ , PapF and PapG. See S . Hultgren et al., Cell 73:887 (1993).
- the pilus is a heteropolymeric surface fiber with an adhesive tip and consists of two major sub-assemblies, the pilus rod and the tip fibrillum.
- the pilus rod is a thick rigid rod made up of repeating PapA subunits arranged in a right-handed helical cylinder whereas the tip fibrillum is a thin, flexible tip fiber extending from the distal end of the pilus rod and is composed primarily of repeating Pap ⁇ subunits arranged in an open helical configuration.
- PapK is thought to link the pilus rod to the base of the tip fibrillum and regulates the length of the tip fibrillum: its incorporation terminates its growth and nucleates the formation of the pilus rod.
- PapF is thought to join the PapG adhesin to the distal end of the flexible tip fibrillum.
- P pili The biogenesis of P pili occurs via the highly conserved chaperone/usher pathway.
- Periplasmic chaperones are required for the assembly of these pili constructed from pilus subunits. In the absence of an interaction with the chaperone, pilus subunits aggregate and are proteolytically degraded.
- Two of the genes in t e pap operon, papD and papC encode the chaperone and usher, respectively.
- Chaperones such as PapD in E. coli are required to bind to pilus proteins imported into the periplasmic space, partition them into assembly component complexes and prevent non-productive aggregation of the subunits in the periplasm. See Kuehn M. J. et al., Proc. Natl.
- PapD is a periplasmic chaperone that mediates the assembly of P pili.
- Periplasmic chaperones along with outer membrane ushers, constitute a molecular mechanism necessary for guiding biogenesis of adhesive organelles in Gram-negative bacteria. These chaperones function to cap and partition interactive subunits imported into the periplasmic space into assembly competent complexes, making non-productive interactions unfavorable.
- PapD binds to each of the pilus subunit types as they emerge from the cytoplasmic membrane and escorts them in assembly-competent, native-like conformations from the cytoplasmic membrane to outer membrane assembly sites comprised of PapC.
- PapC has been termed a molecular usher since it receives chaperone-subunit complexes and incorporates, or ushers, the subunits from the chaperone complex into the growing pilus in a defined order.
- the PapD molecule has two immunoglobulin-like domains oriented in an L shape to form a cleft at their interface.
- the chaperone cleft contains surface-exposed residues that are highly conserved.
- Each immunoglobulin-like domain has a ⁇ -barrel structure formed by two antiparallel ⁇ -pleated sheets with an overall topology similar to an immunoglobulin fold.
- All members of the periplasmic chaperone superfamily have a conserved hydrophobic core that maintains the overall features of the two domains.
- PapD binds to and caps interactive surfaces on pilus subunits and prevents their premature aggregation in the periplasm.
- the chaperone-subunit complexes are targeted to the outer membrane usher where subunits assemble in a specific order to form a pilus. Kuehn et al.
- combinatorial chemistry has become a powerful tool for drug discovery in the pharmaceutical and biotechnology industries.
- combinatorial chemistry is defined as the repetitive and systematic covalent attachment of different structural moieties to one another to produce a mixture of numerous distinct molecular entities or target molecules (i.e., combinatorial libraries); desired target molecules include peptides, oligonucleotides, and small organic molecules.
- Combinatorial chemistry is frequently utilized to generate a group of structurally related analogs which can then be evaluated to establish structure-activity relationships (SAR) and to optimize biological potency.
- SAR structure-activity relationships
- Solid-phase synthesis was developed into a fast and reliable technique for synthesis of peptides almost 40 years ago.
- interest in solid-phase organic synthesis has increased substantially due to the emergence of combinatorial and parallel synthesis strategies that are now being widely applied in pharmaceutical research.
- NMR spectroscopy is a well established technique in solution-phase organic chemistry and appears to be the analytical tool of choice also for solid-phase organic synthesis.
- conventional *H and 13 C NMR spectra of substances attached to a solid support usually suffer from drawbacks such as inhomogeneous line broadening, prolonged spectral acquisition and interference of signals from the solid support.
- the present invention is directed to a compound having the formula:
- each of R protest R 2 and R 3 is independently a substituted or unsubstituted alkyl (C 0 ), substituted or unsubstituted acyl (C 2.15 ), substituted or unsubstituted aryl (C 6 _ ⁇ 4 ), substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl (C 7 .
- R 4 is a carboxy (-CO 2 H), carboxamide (-CONH 2 ), aldehyde (-CHO), boronate (-B(OH) 2 ), phosphonate (PO(OH) 2 ) or ketone (-COR) wherein R is a halogenated or unsubstituted alkyl (C,. 3 ); and the salts, esters and amines thereof.
- Another object of the invention is to provide antibacterial compounds and pharmaceutical compositions containing such antibacterial compounds which have broad specificity for a diverse group of Gram-negative bacteria.
- a further object of this invention is to provide compounds and methods for preventing and inhibiting biofilm formation which comprise administering an effective amount of such compounds to an environment or surface containing Gram-negative bacteria. Additionally, among other objects of the invention is to provide methods for utilizing such compounds, such as methods of treating or preventing Gram-negative infections which comprise providing to a subject an effective amount of the above compositions.
- Another aspect of the present invention is to provide fluorinated linkers for use in the synthesis of the N-substituted amino acid derivatives on solid phase.
- the present invention is also directed to linker compounds having the formula:
- R' is -CO 2 H, -(CH 2 ) n CO 2 H or -O(CH 2 ) n CO 2 H wherein n is between 1 and 10, preferably n is between 1 and 5, and more preferably, n is 1 or 2; and R' 2 and R' 3 is independently fluorine or hydrogen provided that when either R' 2 or R' 3 is fluorine, the other is hydrogen.
- R' 2 of the linker compound is hydrogen and R' 3 of the compound is fluorine.
- a related object of the present invention is to provide processes of synthesis of the above linker compounds. These processes include the steps of hydrolyzing one of the ester moieties of dimethyl-2-fluoroterephtalate, reducing the remaining ester and separating the two regioisomers.
- another process of synthesis includes (a) dealkylating a 2-fluoro-4-propoxybenzoic acid; (b) reducing the carboxylic acid of the product of step (a) thereby producing a hydroxymethylphenol compound; (c) alkylating the phenolic hydroxyl group of the hydroxymethylphenol compound; and (d) hydrolyzing the product of step (c) under basic conditions.
- It is another object of the invention is to provide processes for the synthesis of the antibacterial compounds in solution and on solid phase.
- the process of synthesis of such compounds includes the steps of condensing a compound 6 of Reaction Scheme 1 with a salicyaldehyde selected from the group consisting of the reagent compounds listed in
- the antibacterial compounds are synthesized on solid phase using the linker compounds of the invention.
- Such solid phase synthesis of the compounds include the steps of affixing a linker compound to a solid support to give a benzylic alcohol; subjecting the benzylic alcohol to acylation with bromoacetic acid; subjecting the bromoacetate to a nucleophilic substitution with an amine; acylating with ethyl malonyl chloride thereby forming a N-alkyl-N-(malonamic acid ethyl ester)-glycine derivative; condensing the N-alkyl-N-(malonamic acid ethyl ester)-glycine derivative with a salicyaldehyde; and cleaving the compound from the linker compound under acidic or basic conditions.
- Another process of solid phase synthesis of the antibacterial compounds includes the steps of (a) affixing a linker compound onto a solid support to give a benzylic alcohol; (b) coupling a Fmoc-protected amino acid to the benzylic alcohol thereby producing an amino acid functionalized resin; (c) removing the ⁇ -amino group of the product of step (b); (c) alkylating the ⁇ -amino group of the product of step (c) by reductive alkyation; (d) removing excess aldehyde from the amino acid functionalized resin; (e) acylating with an acid chloride thereby producing a N-(alkylated)- N-(acylated)-amino acid derivative; and (f) cleaving the compound from the linker under acidic or basic conditions.
- a further object of the present invention is to provide an improved method of synthesizing a combinatorial library wherein the improvement comprises affixing a linker compound of the present invention onto a solid support.
- This library of compounds synthesized using this improved synthesis can be used to create a library of compounds which can be screened for antibacterial activity.
- Yet another object of the present invention is to provide methods of monitoring solid-phase synthesis of the antibacterial compounds.
- the process includes the steps of affixing a linker compound onto a solid support, utilizing a means for measuring a signal originating from the linker compound and utilizing the signal as an internal reference thereby enabling the monitoring of reactions of said solid-phase synthesis of compounds.
- the signal originating from the linker compounds will be a 19 F resonance and is measured using 19 F NMR spectroscopy.
- Another related object of the present invention is to provide complexes of the antibacterial compositions complexed to the fluorine linker compounds which are affixed to a solid support.
- Figure 1 represents ⁇ F NMR spectra showing (a) resin-bound linker 2, (b) that ⁇
- Figure 2 represents 19 F NMR spectra of resin-bond products obtained after reductive alkylation of 40 using the reaction conditions given in entries 1-3, Table D.
- the 19p resonance at d -115 ppm originates from the linker and shows that coupling of Fmoc- Phe-OH to 2 was quantitative. This resonance was used as internal standard. Integration of the 19p resonance originating from the -fluorobenzyl residue (d -116 ppm) showed that: (a) the reaction conditions in entry 1 resulted in -64% alkylation of 40, (b) the conditions in entry 2 led to -55% alkylation, and (c) those in entry 3 gave -78% alkylation of 40.
- Figure 3 is a gel-phase ⁇ F NMR spectroscopy of resin-bound products obtained after reductive alkylation of 40, as described in entries 4 - 6, Table D, and subsequent acylation with 4-fluoronaphthoyl chloride.
- the line-broadening in the spectra is due to rotamers about the amide bond in 32a. Integration over the 19p resonances revealed that: (a) use of 1.5 eq. -F-benzaldehyde (entry 4) resulted in -8% dialkylation, (b) increasing the excess ofp-F-benzaldehyde to 3 eq.
- Figure 4 is a gel-phase ⁇ F NMR spectra of 43b obtained after reductive alkylation of 40 with 4,4,4-trifluorobutyraldehyde under the following conditions: (a) 4,4,4- trifluorobutyraldehyde (3 eq.) with direct addition of NaBH3CN gave 43b in 48%, whereas (b) removal of excess aldehyde prior to the addition of NaBH CN increased the yield of 43b to 66%.
- the resins were acylated with 4-fluoronaphthoyl chloride after the reductive alkylation.
- alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof.
- Lower alkyl means alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl, pentyl, hexyl, octyl, cyclopropylenthyl, bornyl and the like.
- alkenyl includes C 2 -C 8 unsaturated hydrocarbons of a linear, branched, or cyclic (C 5 -C 6 ) configuration and combinations thereof.
- alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl and the like.
- alkynyl includes C 2 -C 8 hydrocarbons of a linear or branched configuration and combinations thereof containing at least one carbon-carbon triple bond.
- alkynyl groups include ethyne, propyne, butyne, pentyne, 3-methyl-l-butyne, 3, 3 -dimethyl- 1 -butyne and the like.
- alkoxy refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.
- acyl refers to the group ⁇ C(O)-Z', where Z is a lower alkyl. As used herein, "lower alkyl” means alkyl groups of from 1 to 8 carbon atoms.
- lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl, pentyl, hexyl, octyl, cyclopropylenthyl, bornyl and the like.
- acylamino refers to acylamino groups of from 1 to 8 carbon atoms of a straight, branched or cyclic configuration and combinations thereof. Examples include acetylamino, butylamino, cyclohexylamino and the like.
- aryl and heteroaryl mean a five or six-membered aromatic or heteroaromatic ring containing zero to three heteroatoms selected form O, N, and S; a bicyclic nine or ten-membered aromatic or heteroaromatic ring system containing zero to three heteroatoms selected from O, N, and S; or a tricyclic thirteen or fourteen-membered aromatic or heteroaromatic ring system containing zero to three heteroatoms selected from O, N, and S.
- arylalkyl means an alkyl residue attached to an aryl ring. Examples include, e.g., benzyl, phenethyl and the like.
- carbonyl refers to the group -CO. Examples of organic carbonyl compounds are ketones, aldehydes, carboxylic acids and the like.
- heteroarylalkyl means an alkyl residue attached to a heteroaryl ring. Examples include, pyridinylmethyl, pyrimidinylethyl and the like.
- heterocycloalkyl means a cycloalkyl where one to two of the methylene (CH 2 ) groups is replaced by a heteroatom such as.O, NR' (wherein R' is H or alkyl), S or the like; with the proviso that when two heteroatoms are present, they must be separated by at least two carbon atoms.
- heterocycloalkyls include tetrahydropyranyl, piperidynl, dioxanyl and the like.
- hydrocarbyl is meant a monovalent substituent containing only carbon and hydrogen which may be straight or branched chain, saturated or unsaturated, aromatic or nonaromatic or both and can be cyclic or noncyclic.
- An example of a hydrocarbyl alcohol of 1-lOC could include cyclopentyl ethyl alcohol, 2-pentyl alcohol, 3-butynyl alcohol, 2,4-dimethyl hexyl alcohol, benzyl alcohol and the like.
- carbboxyalkyl means ⁇ C(O)R", wherein R" is alkyl.
- coumarin shall refer to the following structure:
- substituted alkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl means alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl wherein up to three H atoms on each C atom therein are replaced with halogen, hydroxy, loweralkoxy, carboxy, carboalkoxy, carboxamido, cyano, carbonyl, NO 2 , NR R (wherein each R' and R" is H, alkyl or arylalkyl), alkylthio, alkylthiol, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy, and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy or heteroaryloxy.
- Naturally number means a positive number including zero.
- abbreviations used herein for designating the amino acids are based on recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature. See Biochemistry, 11, 1732 (1972).
- Ala, Leu and Gly represent the amino acid residue of L-alanine, L-leucine and glycine, respectively.
- the term “residue” means a radical derived from the corresponding L-amino acid by eliminating the hydroxy portion of the carboxy group and a hydrogen of the ⁇ -amino group.
- amino acid side chain is that part of an amino acid exclusive of the ⁇ CH(NH 2 )COOH portion, as defined by K. D. Kopple, "Peptides and Amino Acids", W. A. Benjamin Inc., New York and
- amino acid side chains are -CH 2 -CH(CH 3 ) 2 (the side chain of leucine), -H (side chain of glycine), -CH 3 (the side chain of alanine), -CH 2 CONH 2 (the side chain of asparagine), -CH 2 SH (the side chain of cysteine), 2- (3-indolyl)-ethyl (the side chain of tryptophan), -CH 2 CH 2 SCH 3 (the side chain of methionine), -CH 2 OH (the side chain of serine), 4-hydroxybenzyl (the side chain of tyrosine), -CH(CH 3 ) 2 (the side chain of valine), benzyl (the side chain of phenylalanine), -CH(CH 3 )CH 2 CH 3 (the side chain of isoleucine), -CH(OH)CH 3 (the side chain of threonine) and the like.
- amino acid side chain includes hydrogen.
- the amino acids and amino acid residues are of the L or D configuration.
- the structures of the compounds of this invention include asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry are included within the scope of this invention. Such isomers are obtained in substantially pure form by classical separation techniques and by sterically controlled synthesis and have arbitrarily been named as isomers L or D, respectively.
- hydrophobic amino acid and “hydrophobic amino acid residue” as used interchangeably herein means the common amino acids and amino acid residues having hydrophobic aromatic or aliphatic side chains which include tyrosine, tryptophan, phenylalanine, histidine, valine, cysteine, leucine, isoleucine, alanine, glycine, and methionine.
- polar amino acid and “polar amino acid residue” as used interchangeably herein means common amino acids and amino acid residues having polar side chains which include serine, threonine, glutamine and asparagine.
- charged amino acid and “charged amino acid residue” as used interchangeably herein means the common amino acids and amino acid residues having charged side chains which include lysine, arginine, aspartic acid and glutamic acid.
- pilus As utilized herein, the term "pilus” or “pili” relates to fibrillar heteropolymeric structures embedded in the cell envelope of many tissue-adhering pathogenic bacteria, notably pathogenic gram negative bacteria.
- pilus and pili will be used interchangeably.
- a pilus is composed of a number of "pilus subunits" which constitute distinct functional parts of the intact pilus.
- chaperone relates to a molecule in living cells which bind to pili subunits during the assembly of pili structures. Many molecular chaperones are involved in the process of pilicide biogenesis. Specialized molecular chaperones are "periplasmic chaperones" which are bacterial molecular chaperones exerting their main actions in the
- periplasmic space constitutes the space in between the inner and outer bacterial cell membrane. Periplasmic chaperones are involved in the process of correct assembly of intact pili structures. When used herein, the use of the term
- chaperone designates a molecular, periplasmic chaperone unless otherwise indicated.
- preventing or inhibiting binding between pilus subunits and a periplasmic chaperone indicates that the normal interaction between a chaperone and its natural ligand, i.e., the pilus subunit, is being affected either by being inhibited, expressed in another manner, or reduced to such an extent that the binding of the pilus subunit to the chaperone is measurably lower than is the case when the chaperone is interacting with the pilus subunit at conditions which are substantially identical (with regard to pH, concentration of ions, and other molecules) to the native conditions in the periplasmic space.
- Measurement of the degree of binding can be determined in vitro by methods known to the person skilled in the art (microcalorimetry, radioimmunoassays, enzyme based immunoassays, surface-plasmon resonance, etc.).
- linker refers to any molecule containing a chain of atoms, e.g., carbon, nitrogen, oxygen, etc., that serves to link the molecules to be synthesized on the support with the support.
- the linker is usually attached to the support via a covalent bond, before synthesis on the support starts, and provides one or more sites for attachment of precursors of the molecules to be synthesized on the support.
- Various linkers can be used to attach the precursors of molecules to be synthesized to the solid phase support.
- solid support refers broadly to supports used in the solid phase synthesis of, for example, peptides, nucleic acids, oligonucleotides, and small organic molecules.
- Solid supports include, but are not limited to, polymer resins (e.g., polyethylene glycol and polystyrene), gels (e.g., polyethylene glycol gels), polyacrylamide/polyethylene glycol copolymer resins, controlled pore glass supports (e.g., the CPG supports commercially available from Millipore), and silica beads and wafers.
- polymer resins e.g., polyethylene glycol and polystyrene
- gels e.g., polyethylene glycol gels
- polyacrylamide/polyethylene glycol copolymer resins e.g., polyacrylamide/polyethylene glycol copolymer resins
- controlled pore glass supports e.g., the CPG supports commercially available from Millipore
- silica beads and wafers e.g., silica beads and wafers.
- antibodies also includes any immuno logically reactive fragment of the immunoglobulins such as Fab, Fab' and F(ab')2 fragments as well as modified immunoreactive forms such as Fv regions, which are produced by manipulation of the relevant genes.
- treatment includes both prophylaxis and therapy.
- the compounds of the invention may be administered to a subject already harboring a bacterial infection or in order to prevent such infection from occurring.
- an effective amount means an amount of the substance in question which will in a majority of subjects have either the effect that the disease caused by the pathogenic bacteria is cured or, if the substance has been given prophylactically, the effect that the disease is prevented from manifesting itself.
- an effective amount also implies that the substance is given in an amount which only causes mild or no adverse effects in the subject to whom it has been administered, or that the adverse effects may be tolerated from a medical and pharmaceutical point of view in the light of the severity of the disease for which the substance has been given.
- subject in need thereof means in the present context a subject, which can be any animal, including a human being, who is infected with, or is likely to be infected with, tissue-adhering pilus-forming bacteria which are believed to be pathogenic.
- the present invention is directed to a novel class of compounds which are effective in preventing or inhibiting pilus biogenesis and activity.
- the compounds of the invention may be effective in treating, preventing and inhibiting bacterial infections caused by Gram-negative organisms.
- the present invention is directed to methods of utilizing such pilicidal compounds and to processes and compositions useful for the synthesis of such pilicidal compounds.
- the compounds of this invention exert their effects by interfering with the function of pilus chaperones to form pili from pilus subunits in the periplasm of the bacterium.
- the compounds of the present invention inhibit or prevent the formation of the complex between PapD and PapG by binding to the
- PapD chaperone thus inhibiting or preventing the formation of the P pili which thereby reduces the capacity of piliated bacteria to attach to host tissues.
- the compounds inhibit the formation of the complex between FimC and FimH, thus inhibiting or preventing the formation of the Type 1.
- Such interference is particularly effective since the inability of the pilus to attach to target tissues results in the loss of ability of the bacteria to infect the tissue.
- each of R protest R 2 and R 3 is independently a substituted or unsubstituted alkyl (C 0 ), substituted or unsubstituted acyl (C 2 . 15 ), substituted or unsubstituted aryl (C 6 .
- R 4 is a carboxy (-CO 2 H), carboxamide (-CONH 2 ), aldehyde (-CHO), boronate (-B(OH) 2 ), phosphonate (PO(OH) 2 ) or ketone (-COR) wherein R is a halogenated or unsubstituted alkyl (C ⁇ ); and the salts, esters and amines thereof.
- any alkyl or alkylene moiety may be selected from the group consisting of halogen, hydroxy, loweralkoxy, carboxy, carboalkoxy, carboxamido, cyano, carbonyl, NO 2 , NR R (wherein each R and R" is H, alkyl or arylalkyl), alkylthio, alkylthiol, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy, and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy or heteroaryloxy.
- the active forms of the compounds of the invention are those wherein the chirality of the carbon at R j is "S.”
- R is -CH 2 SH
- the chirality would be designated "R.”
- the invention includes racemic mixtures which include stereoisomers as well as mixtures of the various diasteriomers, as long as this particular form is included.
- Salts of carboxylic acids include those derived from inorganic bases such as the sodium, potassium, lithium, ammonium, calcium, magnesium, zinc, aluminum and iron salts and the like, as well as those derived from organic, especially nontoxic, bases such as the primary, secondary and tertiary amines, substituted amines including naturally substituted amines, cyclic amines and basic ion-exchange resins. Examples of such compounds capable of forming salts are isopropyl amine, trimethyl amine, triethyl amine,
- 2-dimethyl aminoethanol dicyclohexyl amine, amino acids such as lysine, arginine and histidine, caffeine, procaine, betaene, theobromine, purines, piperazines, and the like.
- the compounds of the present invention may also be in esterified form.
- the esters are prepared from a hydrocarbyl alcohol.
- hydrocarbyl alcohols of C, .10 include but are not limited to, cyclopentyl ethyl alcohol, 2-pentyl alcohol, 3-butynyl alcohol, 2,4-dimethyl hexyl alcohol, benzyl alcohol.
- Particularly preferred are alkyl alcohols.
- Typical examples of alkyl alcohols include but are not limited to, methyl, ethyl, t-butyl, cyclohexyl.
- the alkyl esters of the compounds of the invention are particularly preferred, especially alkyl esters wherein the alcohol contains C,_ 4 .
- each R prison R 2 and R 3 is independently an amino acid residue side chain and R 4 is carboxyl or aldehyde.
- the amino acid residue side chain of each R,, R 2 and R 3 is independently selected from the group consisting of hydrogen, p- hydroxybenzyl, 2-(3-indolyl)-ethyl, benzyl, 5-imidazole, isopropyl, isobutyl, 2- methylpropyl, methyl and 2-thiomethylethyl and more preferably, R [ is hydrogen or p- hydroxybenzyl.
- R is selected from side chains of amino acid residues;
- R 2 is substituted or unsubstituted alkyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl;
- R 3 is substituted or unsubstituted alkyl, aryl, and heteroaryl;
- R 4 is a carboxyl group (- CO 2 H), carboxamide (-CONH 2 ), aldehyde (-CHO), boronate (-B(OH) 2 ) or phosphonate (PO(OH) 2 ).
- R is selected from the side chains of hydrophobic aromatic, hydrophobic aliphatic polar and charged amino acid residues
- R 2 is substituted or unsubstituted arylalkyl or substituted or unsubstituted heteroarylalkyl
- R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl
- R 4 is -CO 2 H or -CHO.
- R is selected from the side chains of hydrophobic aromatic, hydrophobic aliphatic, and polar and charged amino acid residues
- R 2 is substituted or unsubstituted arylalkyl or substituted or unsubstituted heteroarylalkyl
- R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl
- R 4 is -CO 2 H, -CONH 2 or -CHO.
- Yet another preferred embodiment includes compounds wherein K ⁇ is selected from hydrophobic aromatic and hydrophobic aliphatic amino acid residues, R 2 is substituted or unsubstituted arylalkyl or substituted or unsubstituted heteroarylalkyl, R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl and R 4 is - CO 2 H.
- hydrophobic aromatic or aliphatic amino acid residues are tyrosine, tryptophan, phenylalanine, histidine, valine, leucine, isoleucine, alanine, glycine, cysteine and methionine; examples of polar amino acid residues are serine, threonine, glutamine and asparagine; and examples of charged amino acid residues are lysine, arginine, aspartic acid and glutamic acid. It is particularly preferred that R 4 is -CO 2 H as those compounds containing a carboxylic acid functionality demonstrate effective antibacterial properties.
- R is hydrogen, benzyl, 4-aminobutyl and p- hydroxybenzyl;
- R 2 is (CH 2 ) m A wherein m is between 0 and 3 and A is n-butyl, 2- methoxyethyl, benzyl and 2-(3-indolyl)-ethyl;
- R 3 is isobutyl,
- R 4 is carboxyl
- Reaction Schemes 1-3 may be performed in solution or on solid phase.
- Solid-phase synthesis is employed by first coupling a linker compound to a solid support as illustrated by compound 2 in Reaction Scheme 1. This compound affixed to the solid support is used as a linker in solid phase synthesis as exemplified during the synthesis of compounds 9.
- Reaction Scheme 1 reaction conditions: (i) Pentafluorphenol, DIC, EtOAc, TentaGel S NH 2 , 0 °C to room temperature; (/ ) bromoacetic acid, DIC, HOBt, DMAP, THF, room temperature; (iii) 4 ⁇ I-4), CH 3 CN, 0 °C; (iv) ethyl malonyl chloride, DIPEA, CH 2 C1 2 , 0 °C; (v) 7 ⁇ 1-5 ⁇ , piperidine, CH 3 CN, reflux; (vi) aquoeus 1 M LiOH, THF:H 2 O:MeOH (3:1 :1).
- Reaction Scheme 1 is used to synthesize N-substituted glycine derivative compounds, i.e., wherein R, is a hydrogen.
- R is a hydrogen.
- acylation of the benzylic alcohol 2 with bromoacetic acid gives 3.
- this acylation reaction is repeated once in order for complete coupling of bromoacetic acid to occur.
- Nucleophilic substitution of the bromoacetate with an amine in solution gives 5.
- Amidation of 5 with ethyl malonyl chloride gave a N-alkyl-N-(malonamic acid ethyl ester)-glycine 6.
- Reaction Scheme 1 may be utilized to prepare the library of N- substituted glycine-derivative compounds of Table B.
- N-substituted glycine-derivative compounds having the formula:
- R t is hydrogen
- R 2 is (CH 2 ) m A wherein m is between 0 and 3 and A is selected from the group consisting of n-butyl, benzyl and 3-(2-indolyl)-ethyl
- R 3 is coumarin
- R 4 is carboxyl
- solid phase synthesis of these N-substituted glycine-derivative compounds comprise the steps of: affixing a fluorinated linker compound onto a solid support to give a benzylic alcohol; subjecting the benzylic alcohol to acylation with bromoacetic acid; subjecting the bromoacetate to a nucleophilic substitution with an amine; acylating with ethyl malonyl chloride thereby forming a N-alkyl-N-(malonamic acid ethyl ester)-glycine derivative; condensing the N- alkyl-N-(malonamic acid ethyl ester)-glycine derivative with a salicyaldehyde; and cleaving the compound from the linker compound under acidic or basic conditions.
- N-alkyl-N-(malonamic acid ethyl ester)-amino acid derivative (compound 6 of Reaction Scheme 1) may be prepared in solution as described by Simon et al., Proc. Natl. Sci. USA (1992) 89:9367-9371 and Liskamp et al, Chem Eur. J. (1998) 4:1570-1580, which are both incorporated herein by reference.
- Reaction Scheme 2 reaction conditions: (i) 12(7 ⁇ , lib, ethyl bromoacetate, DMF, 0 °C; (t 12(2-4 ⁇ , 11a, Et 3 N, DMF, 70 °C; (iii) ethyl malonyl chloride, DIPEA, CH 2 C1 2 , 0 °C; (iv) 15(7 ⁇ , piperidine, CH 3 CN, reflux; (v) for 16(2-4, 7 ⁇ and 18(2-5, 2-4 ⁇ TFA:H 2 O (2:1), room temperature; (vi) for 13(7 ⁇ pentafluorophenol, DIC, 15(2 ⁇ , EtOAc; for 13(2 ⁇ DIC, 15(2 ⁇ , EtOAc; for 13(5 ⁇ DIPEA, 15(5 ⁇ , CH 2 C1 2 , 0 °C, for 13(5 ⁇ DIPEA, 15(4 ⁇ , CH 2 CL 2 , 0 °C; (vii) for 18(7, 2 ⁇
- N-substituted amino acid compounds 17 and 19 wherein R, is o-amino, n-butyl, benzyl or p-hydroxybenzyl are prepared using the synthesis of Reaction Scheme 2.
- R is o-amino, n-butyl, benzyl or p-hydroxybenzyl
- compound 13 is obtained in solution from a suitable protected amino acid (e.g., Phe, Tyr, Lys) by alkylation with an alkyl halide such as 2-(3-indoyl)-ethyl bromide.
- Compound 13 is then acylated by a carboxylic acid such as 2-napthalene carboxylic acid, which has been activated e.g., as a pentafluorophenyl ester, with a carbodiamine derivative or an acid chloride. Deprotection of the resulting 18 by treatment with an acid, preferablytrifluoroacetic acid, followed by hydrolysis of the ester moiety then gives 19.
- compound 17 is prepared essentially as described above for the synthesis of 9 (Reaction Scheme 1) on solid phase.
- Suitable combinational techniques include those described in U.S. Patent Nos. 5,736,412, 5,840,500, 5,847,150, 5,852,028, 5,856,107, 5,856,496, 5,859,027 and 5,861,532. These techniques can be performed on solid or solution phase.
- the preferred process of the present invention is a "solid phase synthesis" (SPS).
- SPS solid phase synthesis
- Organic synthesis performed on solid phase constitutes an efficient method for preparation of large combinatorial libraries containing structurally distinct molecules.
- the reaction is carried out on macroscopic particles made of material insoluble in the reaction medium.
- a key aspect of any solid-phase synthesis is the choice of a linker compound which will be affixed to the surface of the solid support.
- the linker compound should be orthogonal to the required reaction conditions and allow quantitative cleavage of the product under mild conditions.
- Solid supports e.g., polystyrene resin beads and silica chips
- solid phase synthesis techniques are routinely utilized in generating combinatorial libraries.
- Each derivative is usually prepared in sufficient quantity to permit screening and analysis by conventional methods, e.g., HPLC and mass spectral analysis.
- Applicants have shown that 19 F chemical shifts, as well as linewidths for compounds attached to polyethylene glycol grafted polystyrene resins (TentaGel resins), approach those in solution. See Svensson et al., Tetahedron Lett. 37: 7649-7652 (1996).
- Gel-phase 19 F NMR spectroscopy is well-suited for adoption of solution- phase chemistry to various solid supports and for optimization of reaction conditions.
- the insertion of a fluorine atom into a key position on the linker for use in SPS allows the linker to serve as a diagnostic marker during several of the reactions during solid phase synthesis.
- the fluorine atom of the linker compound allows for the monitoring and optimization of several reactions using 19 F NMR spectroscopy such as the attachment of the linker to the solid phase, coupling of the first building block to the linker and cleavage of the product. Accordingly, the present invention is also directed to a novel class of fluorinated linker compounds having the formula:
- R' is -CO 2 H, -(CH 2 ) n CO 2 H or -O(CH 2 ) n CO 2 H wherein n is between 1 and 10, preferably, n is between 1 and 5, and even more preferably, n is 1 or 2; and R' 2 and R' 3 is independently fluorine or hydrogen provided that when either R' 2 or R' 3 is fluorine, the other is hydrogen.
- Particularly preferred fluorinated linker compounds include, but are not limited to,
- Reaction Scheme 3 reaction conditions: (i) aqueous 1 M LiOH, THF:MeOH:H 2 O (3:1:1), 0 °C to room temperature; (ii) LiBH 4 , THF, 22 53%, 23 40% in two steps; (iii) aqueous Cs 2 CO 3 (20%), MeOH:H 2 O (10:1), then BnBr, DMS, 79%; (iv) TPAP (5 mol%), N- methylmorpholine N-oxide, 4 A molecular sieves, CH 2 C1 2 , 74%; (v) ⁇ aH, (EtO) 2 P(O)CH 2 CO 2 C 2 H 5 , THF, 0 °C, 76%; (vi) Pd/C, H 2 , EtOH:EtOAc (3:1) 4 atm, 88%; (vii) BH 3 -DMS, (CH 3 O) 3 B, THF, 89%; (viii) aqueous 1 M LiOH
- Reaction Scheme 4 reaction conditions: (i) BBr 3 , CH 2 C1 2 , -78 °C to room temperature, 89%; (t0 BH 3 -DMS, (CH 3 O) 3 B, THF, 90%; (iii) BrCH 2 CO 2 C 2 H 5 , DBU, CH 3 CN, reflux, 74%; (iv) aqueous 1 M LiOH, THF:MeOH:H 2 O (3:1:1) 87%.
- linker 1 is prepared by BBr 3 -induced dealkylation of 2-fluoro-4-propoxybenzoic acid, followed by reduction with BH 3 -DMS and (MeO) 3 B to give 3-fluoro-4-hydroxymethylphenol 32.
- linker 1 may be used to monitor the synthesis of another class of potential pilicides consisting of N-alkylated and N-acylated amino acids which are different from the glycine derivations previously described.
- methods for monitoring solid-phase synthesis of such compound include affixing a fluorinated linker compound onto a solid support; utilizing a means for measuring a signal, preferably a 19 F resonance, which originates from the linker compound; andutilizing said signal as an internal reference thereby enabling the monitoring of reactions of said solid-phase synthesis of compounds.
- the 19 F resonance is measured using 19 F ⁇ MR spectroscopy.
- linker 1 is used in combination with gel- phase 19 F ⁇ MR spectroscopy to develop conditions for solid phase synthesis of another class of potential pilicides consisting of N-alkylated and N-acylated amino acids which are different from the glycine derivatives produced in Reaction Scheme 1.
- Applicants utilized the fluorinated linker 1, in combination with fluorinated building blocks, to establish conditions for reductive alkylation of amino acids that could be applied to both aromatic and aliphatic aldehydes.
- Phenylalanine resin 40 was prepared by coupling Fmoc-Phe-OH to 2 in the presence of HOBt, DIC and DMAP, followed by removal of the N -Fmoc protecting group with 20% piperidine in DMF. The ⁇ -amino group in 40 was then alkylated with -fluorobenzaldehyde using ⁇ aBH C ⁇ as reducing agent under different conditions (See Table C of Examples). The ⁇ F resonance originating from the linker moiety of 40 served as internal reference, and integration over the 19p resonance of the N- linked / fluorobenzyl residue enabled evaluation of the outcome of the reactions.
- this method may also be utilized for the reductive alkylation of resin- linked 40 using aliphatic aldehydes.
- removal of excess aldehyde prior to the addition of NaBH3CN i.e. using the conditions of entry 6 in Table C of Example 5, and subsequent acylation furnished 43b.
- Reaction scheme 5 reaction conditions: (i) Pentafluorophenol, DIC, TentaGel S NH2, EtOAc; N ⁇ -Fmoc-Phe-OH, HOBt, DIC, DMAP, THF; (iii) 20% piperidine in DMF; (/v)/>-F-C6H 4 CHO or F3CCH2CH2CHO, MeOH containing 1% HO Ac; then ⁇ aBH 3 C ⁇ ; (v) 4-fluoronaphtoyl chloride, DIPEA, CH2CI2, 0°C to room temperature; (vi) aqueous 1M LiOH, THF:MeOH:H 2 O (3:1 :1).
- solid phase synthesis of a class of potential antibacterial compounds consisting of N-alkylated and N-acylated amino acids which are different from the glycine derivatives are also synthesized using the fluorinated linker compounds.
- solid phase synthesis of such compounds include the steps of: a. affixing a fluorinated linker compound 22, 23, 29 or 1 onto a solid support to give a benzylic alcohol; b. coupling a Fmoc-protected amino acid to the benzylic alcohol thereby producing an amino acid functionalized resin; c. removing the Fmoc-protecting group from the ⁇ -amino group of the product of step (b); d.
- step (c) alkylating the ⁇ -amino group of the product of step (c) by reductive alkyation; e. removing excess aldehyde from the amino acid functionalized resin; f. acylating with an acid chloride thereby producing a N-(alkylated)-N- (acylated)-amino acid derivative; and g. cleaving the compound from the linker under acidic or basic conditions.
- the array of synthesized candidate compounds is screened into relevant assays, e.g., antichaperone or antimicrobial assays, and the compounds are further characterized according to chemical identity and purity using conventional techniques.
- the assay can be scored on a real-time basis and further modifications made accordingly.
- Antichaperone binding activity can be measured by any number of direct methods such as monitoring spectral changes in the compound and/or chaperone, determining the extent of compound binding to immobilized chaperone or vice versa, by indirect methods such as competition assays to determine the extent to which these compounds inhibit chaperone binding to target pilus subunits and/or derivatives (Soto, et al., Embo J..
- Assays to determine the extent of pilus expression in the presence of these compounds may be performed as described in Soto et al., supra, and/or by haemagglutination assays as described in Striker et al., Mol Microbiol. (1995) 16:1021.
- Antibodies to the compounds of the invention may also be produced using standard immunological techniques for production of polyclonal antisera and, if desired, saving the antibody-producing cells of the immunized host for sources of monoclonal antibody production. Techniques for producing antibodies to any substance of interest are well known.
- the immunogenicity of the substance may be enhanced by coupling the hapten to a carrier.
- Carriers useful for this purpose include substances which do not themselves elicit an immune response in the subject mammal. Common carriers used include keyhole limpet hemocyanin (KLH) diptheria taxoid, serum albumin, and the viral coat protein of rotavirus, VP6. Coupling the hapten to the carrier is effected by standard techniques such as contacting the carrier with the compound in the presence of a dehydrating agent such as dicyclohexylcarbodiimide or through the use of linkers.
- KLH keyhole limpet hemocyanin
- the compounds of the invention in immuno genie form are then injected into a suitable mammalian host and antibody titers in the serum are monitored.
- Polyclonal antisera may be harvested when titers are sufficiently high.
- antibody-producing cells of the host such as spleen cells or peripheral blood lymphocytes may be harvested and immortalized.
- the immortalized cells are then cloned as individual colonies and screened for the production of the desired monoclonal antibodies.
- the genes encoding monoclonal antibodies secreted by selected hybridomas or other cells may be recovered, manipulated if desired, for example, to provide multiple epitope specificity or to encode a single-chain form and may be engineered for expression in alternative host cells.
- the antibacterial compositions of the present invention may be utilized to inhibit pili assembly by providing an effective amount of such compositions to a subject.
- the compounds of the invention can be formulated as pharmaceutical or veterinary compositions.
- the mode of administration, and the type of treatment desired, e.g., prevention, prophylaxis, therapy; the compounds are formulated in ways consonant with these parameters.
- a summary of such techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA.
- the dosage of the compounds of the invention is typically 0.1-lOOmg/kg.
- dosage levels are highly dependent on the nature of the infection, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration.
- the dosage of such a substance is expected to be the dosage which is normally employed when administering antibacterial drugs to patients or animals, i.e. 1 ⁇ g - 1000 ⁇ g per kilogram of body weight per day.
- the dosage will depend partly on the route of administration of the substance. If the oral route is employed, the absorption of the substance will be an important factor. A low abso ⁇ tion will have the effect that in the gastro-intestinal tract higher concentrations, and thus higher dosages, will be necessary. Also, the dosage of such a substance when treating infections of the central nervous system (CNS) will be dependent on the permeability of the blood-brain barrier for the substance.
- CNS central nervous system
- the appropriate dosage of the substance should suitably be assessed by performing animal model tests, wherein the effective dose level (e.g. ED 50 ) and the toxic dose level (e.g. TD 50 ) as well as the lethal dose level (e.g. LD 50 or LD 10 ) are established in suitable and acceptable animal models. Dosage levels vary considerably depending on the nature of the infection, the condition of the patient and the frequency and method of administration. Further, if a substance has proven efficient in such animal tests, controlled clinical trials should be performed. Needless to state that such clinical trials should be performed according to the standards of Good Clinical Practice.
- the compounds of the invention may be used alone or in combination with other antibiotics such as erythromycin, tetracycline, macrolides, for example azithromycin and the cephalosporins.
- antibiotics such as erythromycin, tetracycline, macrolides, for example azithromycin and the cephalosporins.
- the compounds will be formulated into suitable compositions to permit facile delivery to the affected areas.
- Formulations may be prepared in a manner suitable for systemic administration or topical or local administration.
- Systemic formulations include those designed for injection (e.g., intramuscular, intravenous or subcutaneous injection) or may be prepared for transdermal, transmucosal, or oral administration.
- the formulation will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like.
- formulations can be prepared in conventional forms as liquid solutions or suspensions or as solid forms suitable for solution or suspension in liquid prior to injection or as emulsions.
- Suitable excipients include, for example, water, saline, dextrose, glycerol and the like.
- compositions may also contain amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
- the compounds can be administered also in liposomal compositions or as microemulsions.
- Suitable dosage forms for oral use include tablets, dispersable powders, granules, capsules, suspensions, syrups, and elixers.
- Inert diluents and carriers for tablets include, for example, calcium carbonate, sodium carbonate, lactose and talc.
- Tablets may also contain granulating and disintegrating agents such as starch and alginic acid, binding agents such as starch, gelatin and acacia, and lubricating agents such as magnesium stearate, stearic acid and talc. Tablets may be uncoated or may be coated by unknown techniques; e.g., to delay disintegration and abso ⁇ tion.
- Inert diluents and carriers which may be used in capsules include, for example, calcium carbonate, calcium phosphate and kaolin.
- Suspensions, syrups and elixers may contain conventional excipients, for example, methyl cellulose, tragacanth, sodium alginate; wetting agents, such as lecithin and polyoxyethylene stearate; and preservatives, e.g. ethyl-p- hydroxybenzoate.
- wetting agents such as lecithin and polyoxyethylene stearate
- preservatives e.g. ethyl-p- hydroxybenzoate.
- sustained release systems for drugs have also been devised as in U.S. Patent No. 5,624,677, which claims a composition providing a relatively slow release of water-soluble drugs for delivery via the sublingual or buccal routes, for example.
- the compounds of the invention are effective in inhibiting a variety of Gram- negative bacteria and have several industrial uses, well known to those skilled in such arts, relating to their antibacterial properties. In general, these uses are carried out by bringing a biocidal or bacterial inhibitory amount of the antibacterial compositions of the present invention into contact with a surface, environment or biozone containing Gram-negative bacteria so that the composition is able to interact with and thereby interfere with the biological function of such bacteria.
- such antibacterial compositions can be used to prevent or inhibit biofilm formation caused by Gram-negative bacteria.
- Compositions may be formulated as sprays, solutions, pellets, powders and in other forms of administration well known to those skilled in such arts.
- the compounds in the invention may be supplied either as a single compound, in a mixture with several other compounds of the invention or in a mixture with additional antimicrobial agents. The following examples are intended to illustrate but not limit the invention.
- Ethyl malonyl chloride (205 ⁇ L, 1.62 mmol) was added to a solution of N-[2- (lH-indol-3-yl)-ethyl]-N ⁇ -BOC-lysine tert-butyl ester (226 mg, 0.54 mmol) and N, N'- diisopropylethylamine (278 ⁇ L, 1.62 mmol) at 0 ° C.
- N-[2-(l//-Indol-3-yl)-ethyl]-N-(malonamic acid ethyl ester)-phenylalanine tert-butyl ester 14 (2 ⁇ .
- Ethyl malonyl chloride (260 ⁇ L, 2.06 mmol) was added to a solution of N-[2- (lH-indol-3-yl)-ethyl]-phenylalanine tert-butyl ester (250 mg, 0.68 mmol) and N, N'- diisopropylethylamine (352 ⁇ L, 2.06 mmol) in C ⁇ 2 C1 2 (20 mL) at 0 °C.
- N N'-Diisopropylcarbodiimide (40 ⁇ L, 0.26 mmol) was added to a solution of N-[2-(lH-indol-3-yl)-ethyl]-phenylalanine tert-butyl ester (50 mg, 0.13 mmol), 2-naphtoic acid (49 mg, 0.27 mmol) and 1-hydroxybenzotriazole (56 mg, 0.41 mmol) in T ⁇ F (5 mL) at 0 °C. The mixture was stirred over night at room temperature and then concentrated.
- N, N'-Diisopropylcarbodiimide (81 ⁇ L, 0.52 mmol) was added to a solution of coumarine- 3-carboxylic acid (100 mg, 0.52 mmol) and w-butylamine (104 ⁇ L, 1.05 mmol) in C ⁇ 2 C1 2 (5 mL) and the solution was stirred at room temperature over night. The precipitate was removed by filtration, the solvent diluted with CH 2 C1 2 (25 mL) and washed with aqueous 0.05 M HCl (2x10 mL), ⁇ aHCO 3 aq.sat. (2x10 mL) and brine (10 mL), dried (MgSO 4 ) and concentrated.
- Benzyl 2-fluoro-4-hydroxymethylbenzoate (24).
- the resultant solution was concentrated to dryness and the residue was concentrated twice from freshly distilled DMF (2x8 mL).
- Benzyl bromide (0.411 mL, 3.47 mmol) was added to a slurry of the solid cesiumsalt in DMF (8 mL), and the reaction solution was stirred over night at ambient temperature. The mixture was concentrated and water was added to the residue.
- Benzyl 4-((E)-2-ethoxycarbonyl-vinyl)-2-fluorobenzoate (26). Tetrapropylammonium perruthenate (TPAP, 5 mg, 0.013 mmol, 5 mol%) was added in one portion to a stirred slurry of 24 (70 mg, 0.269 mmol), 4-methylmo ⁇ holine N-oxide (47 mg, 0.403 mmol) and 4 A molecular sieves (134 mg) in CH 2 C1 2 (5 mL). The resultant slurry was stirred at ambient temperature for 30 min and then filtrated through a pad of silica gel eluted with CH 2 C1 2 (50 mL).
- TPAP Tetrapropylammonium perruthenate
- 2-Fluoro-4-hydroxybenzoic acid (31). 2-Fluoro-4-propoxybenzoic acid (30, 1.21 g, 6.09 mmol) was dissolved in CH 2 C1 2 (16 mL), the solution was cooled to -78 °C and BBr 3 (1 M in CH 2 C1 2 , 18.3 mL, 18.3 mmol) was added. The solution was slowly allowed to reach room temperature and was then stirred at ambient temperature over night. H 2 O (35 mL) was added and the resultant mixture was poured into Et 2 O (20 mL). The water phase was extracted with Et 2 O (4x40 mL) and the combined organic phases were dried (MgSO 4 ).
- Pilicide 9 was finally cleaved from the resin using either aqueous LiOH in THF:MeOH:H2 ⁇ or the optimized conditions based on TFA as described above. In both cases 9 was isolated in 48% yield based on the overall capacity of the resin.
- Resin-bound 7V-alkyl-glycine 5(7-4 ⁇ A solution of each amine 4(7-4 ⁇ (3 eq, 8.10 mmol) in freshly distilled CH 3 C ⁇ (30 mL), for tryptamine freshly distilled DMF was used as solvent, was added to 3 (2.70 mmol, pre-swollen in dry CH 3 CN or DMF) at 0 °C. The resin was agitated at 0 °C for 90 min and then washed with CH 3 CN, MeOH, THF (100 mL each) and dry THF (20 mL) before being dried under vacuum.
- Ethyl malonyl chloride (1.02 mL, 8.10 mmol) dissolved in CH 2 C1 2 (10 mL) was added to a suspension of 5(7-4 ⁇ (2.7 mmol) andN, N'-diisopropylethylamine (DIPEA, 1.38 mL, 8.10mmol) inCH 2 Cl 2 (20 mL) at 0 °C and the resin was agitated at 0 °C for 60 min.
- the resin was washed with CH 2 C1 2 , MeOH, THF (100 mL each) and dry THF (20 mL), and then dried under vacuum.
- Resin-bound 8(7-4, 7-5 ⁇ Each amine of the resins 6(7-4 ⁇ was split into five portions (each approximately 1.9 g resin, 0.54 mmol) which were reacted with the five different salicylaldehydes 7(7-5 ⁇ .
- a solution of each salicyaldehyde (3 eq., 1.54 mmol) in freshly distilled CH 3 C ⁇ (7 mL) was added to 6(7-4 ⁇ which had been pre-swollen in CH 3 CN.
- the mixture was heated to reflux as piperidine (1.2 eq., 61 ⁇ L , 0.62 mmol) in CH 3 CN (1 mL) was added. After refluxing over night the resin allowed to reach room temperature before being washed with CH 3 CN, MeOH, THF (each 50 mL) and dry THF (10 mL). Then the resin was dried under vacuum.
- Resin-bound phenylalanine (23). DIC (201 ⁇ L, 1.30 mmol) was added to a solution of Fmoc-Phe-OH (604 mg, 1.56 mmol) and HOBt (140 mg, 1.04 mmol) in dry THF (4 mL). After 1 h, the activated amino acid and DMAP (21 mg, 0.17 mmol, dissolved in dry THF, 1 mL) were added to 2 (2.0 g, 0.52 mmol, pre-swollen in dry THF) and the mixture was agitated at ambient temperature over night. After filtration the resin was washed with THF, MeOH and THF (50 mL of each solvent), and dried over vacuum.
- Entries 4 and 5 Reductive alkylation was performed as described for entry 3 using 40 (100 mg, 26 ⁇ mol), but with larger amounts of/ fluorobenzaldehyde (4.2 ⁇ L, 39 ⁇ mol for entry 4; 8.4 ⁇ L, 78 ⁇ mol for entry 5) and NaBH3CN (8 mg, 130 ⁇ mol for entry 4; 11 mg, 182 ⁇ mol for entry 5).
- N-(4-Fluorobenzyl)-JV-(4-fluoronaphtoyl)-phenylalanine 44.
- Solid-phase reductive alkylation of 40 was performed as described in entry 6 above by treatment of resin 40 (1.0 g, 0.26 mmol) with/j-fluorobenzaldehyde (84 ⁇ L, 0.78 mmol) and NaB ⁇ CN (114 mg, 1.82 mmol).
- Acylation of the resulting resin was accomplished using 4-fluoronaphtoyl chloride (162 mg, 0.78 mmol) and DIPEA (130 ⁇ L, 0.78 mmol) as described above.
- Compound 44 was cleaved from the resin using aqueous LiOH (1 M, 4 mL) in THF:MeOH:H2 ⁇ (3:1:1; 40 mL) at ambient temperature for 2 h. After filtration and subsequent washing of the resin with HOAc and THF (80 mL of each solvent), the filtrate was concentrated and finally co-concentrated from toluene (3x50 mL). The residue was dissolved in a mixture of EtOAc (30 mL) and aqueous HCl (0.05 M, 10 mL). The water phase was separated and acidified with aqueous HCl (1 M) and extracted with EtOAc (2x30 mL). The combined organic layers were dried (Na2SO4) and concentrated.
- PapD 50 ⁇ g/mL in 10 mM NaAc pH 5.5
- FimC 50 ⁇ g/mL in 10 mM NaAc pH 5.5
- This procedure was also employed for coupling of non-target proteins. Immobilization levels of 6-8 000 RU were obtained. Unmodified dextrane in one of the flow cells was used as reference surface.
- the compounds were prepared as described in Examples 1 and 2 and diluted from 10 mM DMSO stock solutions to a final concentration of 100 ⁇ M or 10 ⁇ M in running buffer (67 mM phosphate buffer (9.6 g Na 2 HPO 4 •2H 2 O, 1.7 g KH2PO4, 4.1 g NaCl, 1000 mL H 2 O), 3.4 mM EDTA, 0.01% Tween, 5% DMSO, pH 7.4.) so that the concentrations of DMSO and buffer substances were carefully matched.
- the compounds were injected (flow rate was 30 ⁇ l/min at 25 °C) and the binding of the compounds to the immobilized chaperone proteins was observed on real time.
- the surface was regenerated by injection of 10 mM glycine » HCl, pH 2.0. To avoid carry over, the flow system was washed with a 1 : 1 mixture of DMSO and H2O.
- the compounds were injected (flow rate was 30 ⁇ l/min at 25 °C) at a concentration of 100 ⁇ M in duplicate or triplicate and in random order.
- the surface was regenerated by injection of 10 mM glycine*HCl, pH 2.0.
- the flow system was washed with a 1:1 mixture of DMSO and H2O. Reference chemicals were used as negative controls.
- Table D Affinity of Compounds for PapD and FimC.
- Example 7 Inhibition Assay Using FimC ⁇ Reconstitution Assay
- Applicants conducted a reconstitution assay using FimCH and PapDG.
- the FimCH complex was brought to 3M Urea in 20mM MES pH 6.8 and injected onto a 1ml Source 15S Pharmacia column (lml/min flow rate) and pure FimH was collected in the Flow Through.
- the PapDG complex was brought to 5M Urea in 20mM MES pH 6.8 and injected onto a 1ml Source 15S Pharmacia column (lml min flow rate) and pure Pap D was collected in the Flow Through.
- PapG in 5M Urea was diluted lOfold volume into
- the candidate compounds were synthesized as described in Examples 1 and 2. For the tested compounds, a 38 M excess was preincubated with the PapD (or FimC) for 15 minutes and the same reconstitution and PapDG (or FimCH) separation was performed. Binding of the compounds to the chaperones in the column were detected using UV light (UVA 280). Peak areas were calculated as a percent of wild type.
- Table E represents the library of compounds evaluated for the inhibition of formation of the complex between PapD and PapG; the % inhibition of the complex between PapD and PapG at an inhibitor/PapD ratio of 38.
- Compound 9(4, 1 ⁇ was also evaluated as an inhibitor of FimCH complex formation. It gives 18% inhibition at a 69 fold excess as compared to FimC and 60% inhibition at a 207 fold excess.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78320/00A AU7832000A (en) | 1999-09-23 | 2000-09-22 | Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15582299P | 1999-09-23 | 1999-09-23 | |
US60/155,822 | 1999-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001020995A1 true WO2001020995A1 (en) | 2001-03-29 |
WO2001020995A9 WO2001020995A9 (en) | 2002-11-14 |
Family
ID=22556940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/026177 WO2001020995A1 (en) | 1999-09-23 | 2000-09-22 | Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7832000A (en) |
WO (1) | WO2001020995A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887877B2 (en) | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
CN102653532A (en) * | 2012-04-24 | 2012-09-05 | 云南烟草科学研究院 | Lignans compound in aromatic tobacco and preparation method and application of lignans compound |
US8283367B2 (en) | 2005-02-11 | 2012-10-09 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US8541590B2 (en) | 2009-12-22 | 2013-09-24 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
KR101620093B1 (en) | 2010-08-23 | 2016-05-13 | 주식회사 녹십자메디스 | New coumarin derivative and process for preparing the same |
US10583119B2 (en) | 2008-04-21 | 2020-03-10 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
CN111592660A (en) * | 2020-06-15 | 2020-08-28 | 平顶山学院 | One-dimensional coordination polymer of nickel, preparation method thereof and application thereof in proton conducting membrane of fuel cell |
-
2000
- 2000-09-22 AU AU78320/00A patent/AU7832000A/en not_active Abandoned
- 2000-09-22 WO PCT/US2000/026177 patent/WO2001020995A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
SVENSSON ET AL.: "Fluorinated linkers for monitoring solid-phase synthesis using gel-phase 19F NMR spectroscopy", TETRAHEDRON LETT., vol. 39, 24 September 1998 (1998-09-24), pages 7193 - 7196, XP002936202 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887877B2 (en) | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
US8546608B2 (en) | 2003-08-14 | 2013-10-01 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US9233115B2 (en) | 2003-08-14 | 2016-01-12 | Millennium Pharmaceuticals Inc. | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7915236B2 (en) | 2003-08-14 | 2011-03-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US8058262B2 (en) | 2003-08-14 | 2011-11-15 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US8283367B2 (en) | 2005-02-11 | 2012-10-09 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
US10583119B2 (en) | 2008-04-21 | 2020-03-10 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
US8541590B2 (en) | 2009-12-22 | 2013-09-24 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
KR101620093B1 (en) | 2010-08-23 | 2016-05-13 | 주식회사 녹십자메디스 | New coumarin derivative and process for preparing the same |
CN102653532A (en) * | 2012-04-24 | 2012-09-05 | 云南烟草科学研究院 | Lignans compound in aromatic tobacco and preparation method and application of lignans compound |
CN102653532B (en) * | 2012-04-24 | 2015-02-18 | 云南烟草科学研究院 | Lignans compound in aromatic tobacco and preparation method and application of lignans compound |
CN111592660A (en) * | 2020-06-15 | 2020-08-28 | 平顶山学院 | One-dimensional coordination polymer of nickel, preparation method thereof and application thereof in proton conducting membrane of fuel cell |
Also Published As
Publication number | Publication date |
---|---|
WO2001020995A9 (en) | 2002-11-14 |
AU7832000A (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111886020B (en) | Peptide macrocycles against acinetobacter baumannii | |
US5672598A (en) | Lactam-containing hydroxamic acids | |
JP4157601B2 (en) | Substituted oxazolidine calpain and / or cathepsin B inhibitor | |
JP5911503B2 (en) | Dipeptide analogs for treating amyloid fibril formation-related conditions | |
JP2008508348A (en) | Compounds for inhibiting copper-containing amine oxidase and uses thereof | |
US20070066646A1 (en) | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | |
PT101027A (en) | Process for their preparation and their use as pharmaceutical compositions | |
JP6437443B2 (en) | Macrocyclic wide-area antibiotics | |
DE60019954T2 (en) | FAB I HEMMER | |
CA2096225A1 (en) | Matrix metalloprotease inhibitors | |
KR19980086893A (en) | Substituted diaminocarboxylic acids | |
JPH10512241A (en) | Hydroxamic acid-containing inhibitors of matrix metalloproteases | |
AU3944593A (en) | 4-(4'-piperidinyl or 3'-pirrolidinyl) substituted imidazoles as H3-receptor antagonists and therapeutic uses thereof | |
JPH06340693A (en) | New polypeptide compound and its salt | |
EP0648206A1 (en) | Peptidyl derivatives and their use as metalloproteinase inhibitors | |
WO2001020995A1 (en) | Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof | |
HUT52525A (en) | Process for producing retroviral proteaz-inhibitors and pharmaceutical compositions containing them as active components | |
TW200524578A (en) | Protease inhibitors | |
JP2005530809A (en) | Phenylcyclohexylpropanolamine derivative, process for its preparation and therapeutic application thereof | |
JP2012067103A (en) | Peptoid compound | |
JP4927566B2 (en) | PAR-2 agonist | |
FI88295C (en) | FAR OIL FRAMSTAELLNING AV NYA, THERAPEUTIC ANVAENDBARA 5-CARBONYLAMINO-4-HYDROXI-N-HEXANAMIDER | |
JPH09509657A (en) | Intermediates and methods for manufacturing | |
JP6118892B2 (en) | Cyclic prodrugs of duocarmycin analogs | |
IT8009577A1 (en) | NEW 1-OXADETIACEPHALOSPORIN DERIVATIVES, THEIR PRODUCTION, AND THEIR USE AS ANTIBACTERIALS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |